84 results
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
risk of early death Tolerance Swelling Carpel Tunnel Thyroid Respiratory Arthritis Hypertrophy Issues Pituitary Tumor Somatostatin Receptor Ligands … reduction 3 (6%) 1 (2%) Leading to rescue 2 (4%) 13 (23%) Leading to death 0 0 20
Paltusotine Demonstrated No New Safety Signals TEAEs
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
) Leading to discontinuation 2 (5.6) Serious 4 (11.1) Death 1 (2.8)* Treatment-related 16 (44.4) Mild/Moderate 16 (44.4) Severe 0 Leading … to discontinuation 0 Serious 0 Death 0 Preliminary Safety Summary from Ongoing Carcinoid Syndrome Phase 2 Study Paltusotine was generally well-tolerated
8-K
EX-10.1
CRNX
Crinetics Pharmaceuticals Inc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
estate planning purposes,
(ii) upon death by will, testamentary document or intestate succession,
(iii) if the undersigned is a natural person, to any … ,
(viii) to the Company from an employee of the Company upon death, disability or termination of employment, in each case, of such employee, or
(ix
8-K
EX-99.2
v6kp9 yodl3d
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
2nn1c2ncvnsyir
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
424B5
van2lgq7
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
qjp o761acjs
11 Sep 23
Prospectus supplement for primary offering
4:09pm
8-K
EX-99.2
ohd ezum0zv2
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
sxpmr2uhfys0f wmvk
3 Oct 22
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
8:30am
424B5
uollpjx4rr2y3yh jw
12 Aug 22
Prospectus supplement for primary offering
8:31am